Search Results - "Mandelin, P.M."

Real-World Toxicity of Conventional Versus Hypofractionated Definitive Prostate Radiotherapy across a Large, Diverse, Academic and Community-Based Enterprise by Ladbury, C.J., Watkins, W.T., Mason, J.M., Kalash, R., Ronson, B.B., Ash, R.B., Mandelin, P.M., Menzel, P.L., Li, Y.R., Wong, J.Y.C., Lee, P., Sampath, S., Dandapani, S.V., Glaser, S.M.

“…Over the past 10-15 years there has been increasing adoption of moderate hypofractionation (HF) for definitive prostate radiotherapy as compared to…”
Get full text

Initial Results of a Phase 2 Trial of Stereotactic Body Radiation Therapy, Hormone/Androgen Deprivation Therapy and Radium 223 Dichloride for Oligometastatic Castrate Sensitive Prostate Cancer (SHARP) by Dandapani, S.V., Hao, C., Ladbury, C.J., Wong, J.Y.C., Li, Y.R., Liu, J.R., Glaser, S.M., Lee, P., Mandelin, P.M., Pal, S.K., Alcantara, M., Kortylewski, M., Frankel, P., Ruel, C., Chehrazi-Raffle, A., Lyou, Y., Liu, J., Simpson, J., Dorff, T.B., Twardowski, P.

“…While radium 223 dichloride (Ra-223) has been approved for metastatic castrate resistant prostate cancer, there is limited prospective data regarding its use…”
Get full text